As its predicted GLP-1 use will continue to rise in OSA patients, a common topic in discussions, according to Peters, is how GLP-1s might affect the use of other sleep apnea therapies, like CPAP, oral appliances, and hypoglossal nerve stimulation
Heres the strategic breakdown: Why this matters AUD remains severely underserved globally high relapse rates, limited therapeutic innovation, huge societal burden
The standard recommendation for weight-loss phases with GLP-1 agonists is 1.2 to 1.6 grams of protein per kilogram of target body weight per day
Marissa Liza: And she didn't notice any difference
Cultural narratives about willpower, personal responsibility, and moral failure in obesity create receptivity to messages that frame medication as cheating, addiction, or dangerous shortcuts
And any supplementation that they take besides glutaryl, it's not gonna raise the levels to high normal